Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder

Vistagen (NASDAQ: VTGN) presented positive exploratory data at Psych Congress 2026, indicating a potential efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in patients with very severe social anxiety disorder. The research involved a public speaking challenge study and showed that participants with a Liebowitz Social Anxiety Scale (LSAS) score of 95 or higher experienced improvements in anxiety symptoms after treatment with fasedienol compared to placebo. The findings were supported by analyses from two randomized, double-blind, placebo-controlled clinical trials.